HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Taro Pharmaceuticals Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Taro Pharmaceuticals Intelligence Report

Generated from 2 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 68%

Evidence

12 items

Sources

11

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Taro Pharmaceuticals maintains an active intelligence profile across Dermatology, Acne, Neurology, Anticonvulsant. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 68% across 3 tracked sources. Highest-priority development: S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Taro Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    Clinical Outcome Assessments (COA) Qualification Program Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Real-World Evidence Submissions to the Center for Drug Evaluation and Research

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    FDA TA — AZELAIC ACID (ORIG)

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    FDA TA — ANDA220639

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    FDA AP — VYEPTI (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — NGENLA (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Clinical trials for medicines: modifying a clinical trial approval

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 43 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical Outcome Assessments (COA) Qualification Program Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Real-World Evidence Submissions to the Center for Drug Evaluation and Research

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — AZELAIC ACID (ORIG)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA TA — ANDA220639

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — VYEPTI (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — NGENLA (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: modifying a clinical trial approval

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications

    Moderate Confidence · 84%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • TARO's ANDA219052 for PERAMPANEL Receives Approval Status

    Neurology · Anticonvulsant

  • FDA Submission Update for Azelaic Acid by Taro Pharmaceuticals

    Dermatology · Acne

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.